TASS informs about this with reference to the general director of the center, corresponding member of the Russian Academy of Sciences Aidar Ishmukhametov.
“On October 6, we began clinical trials of our vaccine in Novosibirsk.
We expect to finish the first and second phases of testing in November and, if everything is successful, we will move on to the third phase, ”he said.
He said that the center's vaccine is "whole-virion inactivated", and noted that "the vast majority of vaccines in the world are whole-virion, this is by far the most mature approach."
Ishmukhametov explained that "such vaccines have a low protein load, that is, vaccines are given in a very sparing dose for the subjects, and the number of potential complications is therefore minimal."
“Our Institute for Technology of Creation of Whole Virion Vaccines has been operating for over 50 years,” he added.
Earlier, Russian Health Minister Mikhail Murashko said that a large-scale introduction of the Sputnik V coronavirus vaccine into civilian circulation could begin in October.